Champions Oncology, Inc.

NASDAQ:CSBR

Biotechnology

Healthcare
$4.44 -1.17%

-$0.08 today

Market cap
$61.80M
Beta
0.40
P/E (TTM)
-41.0
EPS (TTM)
-$0.16
52W Low $5.50High $9.63

Volume 0.01M

Average 0.01M

CSBR Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Champions Oncology, Inc.NASDAQ: CSBR

Gross Margin · Q3 FY2026 · quarter ended Jan 2026

Gross margin narrows to 46.7%

Gross margin was 46.7% in Q3 FY2026, down 14.5 pp from a year earlier. On a trailing-twelve-month basis it was 45.9%, down 5.7 pp year over year. Over 3 fiscal years it narrowed by 1.7 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJan 2026
46.7%-5.0 pp QoQ
Last fiscal yearApr 2025
50.1%+8.8 pp YoY
LTMJan 2026
45.9%-5.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-14.5 pp——
1 year+8.8 pp——
3 years-1.7 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
50.1%
Year-over-year change
+8.8pp

Gross Margin vs competitors

How CSBR compares with its peers on the latest reported figures

  • CSBR's LTM Jan 2026 gross margin of 45.9% is the 4th highest of the 8 companies compared; the peer median is 0.7%.
  • Its year-over-year change of -5.7 pp is the 4th highest of 7, against a peer median of -60.1 pp.
  • Over three fiscal years its change of -1.7 pp compares with a peer median of +282.7 pp.
CSBR Competitors Peer median
Gross Margin for CSBR and competitors
Company Period LTM level YoY 3-year change
CNTBConnect Biopharma Holdings LimitedFY2025100.0% +0.0 pp—
STROSutro Biopharma, Inc.LTM Mar 202698.7% +1.4 pp+5.1 pp
ATRAAtara Biotherapeutics, Inc.LTM Mar 202696.1% +15.9 pp+407.1 pp
CSBRChampions Oncology, Inc.LTM Jan 202645.9% -5.7 pp-1.7 pp
ORMPOramed Pharmaceuticals Inc.FY20250.7% —-99.4 pp
IMAImageneBio IncFY2025-29.1% -129.1 pp+282.7 pp
STTKShattuck Labs, Inc.LTM Mar 2026-82.0% -120.1 pp+12607.2 pp
IFRXInflaRx N.V.LTM Mar 2026-24646.3% -22352.6 pp—
ARTVArtiva Biotherapeutics, Inc.FY2025— ——
KLRSKalaris Therapeutics IncFY2025— ——
Peer median (excluding CSBR) 0.7%-60.1 pp+282.7 pp

Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Apr 2021
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Revenue41.04M49.11M53.87M50.16M56.94M
Cost of Revenue21.45M23.63M29.53M29.4M28.39M
Gross Profit19.59M25.48M24.34M20.75M28.56M
Gross Margin47.7%51.9%45.2%41.4%50.1%
Research & Development7.2M9.37M11.55M9.54M6.83M
Selling, General & Admin12.03M15.5M17.24M18.13M16.88M
Operating Expenses19.23M24.87M28.79M27.68M23.71M
Depreciation & Amortization1.18M1.63M2.25M1.87M1.64M
EBITDA1.55M2.21M(3.02M)(5.44M)6.27M
EBITDA Margin3.8%4.5%-5.6%-10.8%11.0%
Operating Income366K607K(4.45M)(6.92M)4.85M
Operating Margin0.9%1.2%-8.3%-13.8%8.5%
Interest Income00000
Interest Expense00000
Other Income / Expenses71K(24K)(818K)(387K)(220K)
Income Before Tax437K583K(5.27M)(7.31M)4.63M
Pre-Tax Margin1.1%1.2%-9.8%-14.6%8.1%
Income Tax Expense75K35K68K(32K)(75K)
Net Income362K548K(5.34M)(7.28M)4.7M
Net Margin0.9%1.1%-9.9%-14.5%8.3%
EPS (Basic)0.030.04(0.39)(0.54)0.34
EPS (Diluted)0.020.04(0.39)(0.54)0.33
Weighted Avg Shares13.14M13.2M13.54M13.55M13.66M
Weighted Avg Shares (Diluted)14.57M14.16M13.54M13.55M14.27M

Champions Oncology, Inc.

NASDAQ:CSBR

Intrinsic Alpha fair value

Locked

Current Price

$4.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.